Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The recent modifications of the French bioethics law, the therapeutic progress and the massive development of advanced genetic techniques (such Next-Generation Sequencing (NGS)) with a rapid decrease in costs imply to question the extension of Newborn Screening (NBS) to new actionable pathologies and the acceptable and relevant methods for its possible expansion. International studies are beginning to determine the potential place of NGS in NBS. In this perspective, the SeDeN project aims to fully assess the social acceptability of these issues by measuring the diversity and consistency of expectations of French health professionals, parents and public policy makers.
The SeDeN-p3 Study focuses on the opinions of parents. It aims to analyze the perception of parents in different situations: birth, early childhood, child screened in the framework of the national neonatal screening program, etc. The objective of this part is to study the understanding and expectations of parents in France regarding the extension of newborn screening as well as their preferences regarding its conditions (information, types of pathologies, screening methods, etc.).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Population 1Q | Parents or co-parents of a newborn child. |
| |
| Population 2 | Parents or co-parents whose youngest child is 1 week to 3 years old. |
| |
| Population 3 | Parents or co-parents whose child had a suspicious newborn screening result that was confirmed at the diagnosis phase (except hearing). |
| |
| Population 4 | Parents or co-parents whose child was diagnosed later based on clinical signs for diseases not included in the list of diseases screening in French newborn screening, but included in the list of diseases screened in newborn screening in other countries. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Questionnaire | Other | Online self-administered questionnaire to quantitatively mesure parental knowledge and expectations on current and expanded newborn screeing and parental acceptability of expanded newborn screening using genetic. |
| Measure | Description | Time Frame |
|---|---|---|
| Mixed matrix of parental acceptability dimensions of expanded newborn screening (Mixed-data matrix) | Mixed method design used to measure parental acceptability composed of quantitative and qualitative data | November 2023 |
| Measure | Description | Time Frame |
|---|---|---|
| Parental acceptability scores for expanded newborn screening (Theorical Framework of Acceptability scores in self-administered questionnaire to measure parental acceptability) | November 2023 | |
| Typology of parental acceptability scores for expanded newborn screening (Classification) |
Not provided
Inclusion Criteria:
All populations combined:
Be a parent or co-parent
Age of parent:
Live in metropolitan France
Have received information about the SeDeN-p3 Study
Understand the purpose of the SeDeN-p3 Study
Self-administered questionnaire:
Be able to read and answer a self-administered questionnaire in French
Have a child less than a week old
Have just giver birth in 1 of the partner maternity hospitals during the survey period
Parent or co-parent whose youngest child is between 1 week and 3 years old
Be part of the panel of the selected survey-sample firm
Semi-structured interviews
Can converse fluently in French
Accept to conduct a recorded interview
Have completed the entire questionnaire
Have a child under 5 years old (inclusive) with 1 of the following diseases :
Phenylketonuria
Congenital hypothyroidism
Congenital adrenal hyperplasia
Cystic fibrosis
Sickle cell disease
hearing loss
MCAD deficiency
glutaric aciduria type -1
isovaleric academia
LCHAD deficiency
carnitine deficiency
homocystinuria
leukinosis
tyrosinemia type 1
Have a child under 17 years old (inclusive), with 1 of following diseases:
Exclusion Criteria:
Not provided
Not provided
Parents or co-parents in France with a sick child or not
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital Antoine Beclere - Aphp | Clamart | 92140 | France | |||
| Chu Dijon Bourgogne |
Not provided
| ID | Term |
|---|---|
| D011795 | Surveys and Questionnaires |
| D007407 | Interviews as Topic |
| ID | Term |
|---|---|
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D017531 | Health Care Evaluation Mechanisms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Interview | Other | Semi-structured interview to explore parental representations on the extension of newborn screening and - if concerned - to retrace the screening/diagnosis/care management pathway |
|
| November 2023 |
| Measure of importance given to different modalities of information about newborn screening (by whom, when, how, etc.) (Multiple Choice Questions) | November 2023 |
| Parent opinion on newborn screening for Spinal Muscular Atrophy, Duchenne muscular dystrophy, BRCA-related breast and ovarian cancer predisposition syndrome and congenital long QT | (5-point Likert scale for agreement and thematic content analysis of the free comment areas) | November 2023 |
| Parent's views on the use of genetic testing in expanded newborn screening (Likert scales) | November 2023 |
| Description of acceptability of expanded newborn screening to parents of a sick child (Thematic content analysis) | April 2024 |
| Dijon |
| 21000 |
| France |
| Hôpital Necker - Enfants Malades | Paris | 75015 | France |
| Groupe Hospitalier de La Haute-Saône | Vesoul | 70000 | France |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |